- Joined
- Nov 11, 2013
- Messages
- 5,396
And don't forget pharmaceutical and equipment providers.
Pharmaceutical spending per capita in selected countries as of 2018(in U.S. dollars)
Per capita spending in U.S. dollars
United States 1,220
Switzerland 963
Canada* 832
Japan 838
Germany 823
Belgium 689
Australia 673
Korea* 660
France 653
Austria 646
Greece 603
Italy* 601
Ireland 599
https://www.statista.com/statistics/266141/pharmaceutical-spending-per-capita-in-selected-countries/
Americans use fewer prescription drugs, and when they use them, they are more likely to use cheaper generic versions. Instead the discrepancy can be traced back to the issue plaguing the entirety of the U.S. health care system: prices.
The number of drugs grossing more than $1 billion in sales increased from six in 1997 to 52 in 2006. The recent introduction of extremely pricey drugs treating hepatitis C are only the latest of these.
Lacking even rudimentary price controls, U.S. consumers bore the full brunt of the expensive development work that goes into new drugs. These costs were further augmented by marketing expenditures and profit seeking by all entities within the pharmaceutical supply chain. Consumers in Europe, where there are government-controlled checks on prices, were not as exposed to those high costs.
https://theconversation.com/why-the-us-has-higher-drug-prices-than-other-countries-111256
Pharmaceutical spending per capita in selected countries as of 2018(in U.S. dollars)
Per capita spending in U.S. dollars
United States 1,220
Switzerland 963
Canada* 832
Japan 838
Germany 823
Belgium 689
Australia 673
Korea* 660
France 653
Austria 646
Greece 603
Italy* 601
Ireland 599
https://www.statista.com/statistics/266141/pharmaceutical-spending-per-capita-in-selected-countries/
Americans use fewer prescription drugs, and when they use them, they are more likely to use cheaper generic versions. Instead the discrepancy can be traced back to the issue plaguing the entirety of the U.S. health care system: prices.
The number of drugs grossing more than $1 billion in sales increased from six in 1997 to 52 in 2006. The recent introduction of extremely pricey drugs treating hepatitis C are only the latest of these.
Lacking even rudimentary price controls, U.S. consumers bore the full brunt of the expensive development work that goes into new drugs. These costs were further augmented by marketing expenditures and profit seeking by all entities within the pharmaceutical supply chain. Consumers in Europe, where there are government-controlled checks on prices, were not as exposed to those high costs.
https://theconversation.com/why-the-us-has-higher-drug-prices-than-other-countries-111256
